P/B
3,8
Puma Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
$531.2M
Market Cap • 10/9/2026
2007
(19 years)
Founded
2012
(14 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
2,3
P/EBITDA
13
P/OCF
12,9
P/FCF
12,9
P/E
19,8
BVPS
2,7
EPS
0,5
Market Cap
Market Cap
531,2M
EV
442,1M
EV/Revenue
1,9
EV/EBITDA
10,8
EV/EBIT
14,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-1,3B
Profitability
Gross Margin
74,8%
EBITDA Margin
17,7%
EBIT Margin
13,2%
Net Margin
11,6%
D&A/EBITDA
0%
R&D/Revenue
30,9%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
17,3%
% PPE
2,3%
% Goodwill
0%
ROE
22%
ROIC
35,7%
Growth
CAGR Revenue 5Y
-1,9%
CAGR OCF 5Y
28,7%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
2,9
Quick Ratio
2,6
Interest Coverage
864,9%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!